ArticleEpigenetics2014
Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.
Article in Epigenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- COMP-PMEPA1 axis promotes epithelial-to-mesenchymal transition in breast cancer cells.Molecular oncology · 2026Article
- Methylation reprogramming associated with aggressive prostate cancer and ancestral disparities.Molecular systems biology · 2025Article
- PMEPA1-Mediated Treg Cell Impairment Promotes Endometrial Stromal Invasion via Excessive PI3K/AKT Signaling in Endometriosis.Current medical science · 2025Article
- Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.JHEP reports : innovation in hepatology · 2024Article
- Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer.Epigenetics · 2023Article
- Steadfast Toll Like Receptor 4 (Genes · 2023Article
- Prostate transmembrane androgen inducible protein 1Frontiers in oncology · 2023Review
- Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients.Frontiers in oncology · 2023Review
- Unraveling the Potential Role of NEDD4-like E3 Ligases in Cancer.International journal of molecular sciences · 2022Review
- Study on the cellular internalization mechanisms andDrug delivery · 2020Article
- Review
- Characterization of uniqueOncotarget · 2020Article
- RETRACTED: Analysis ofCancers · 2019Article
- Epigenetic analysis identifies factors driving racial disparity in prostate cancer.Cancer reports (Hoboken, N.J.) · 2019Article
- DNA methylation profiles in African American prostate cancer patients in relation to disease progression.Genomics · 2019Article
- Development of Novel Monoclonal Antibodies for Evaluation of Transmembrane Prostate Androgen-Induced Protein 1 (TMEPAI) Expression Patterns in Gastric Cancer.Pathology oncology research : POR · 2018Article
- CD38 is methylated in prostate cancer and regulates extracellular NADCancer & metabolism · 2018Article
- Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer.Oncotarget · 2016Article
- Kdm6b and Pmepa1 as Targets of Bioelectrically and Behaviorally Induced Activin A Signaling.Molecular neurobiology · 2016Article
- Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
The prostate transmembrane protein androgen induced 1 (PMEPA1) gene is highly expressed in prostate epithelial cells and is a direct transcriptional target for the androgen receptor (AR). AR protein levels are controlled by the AR-PMEPA1 negative feedback loop through NEDD4-E3 ligase. Reduced expression of PMEPA1 observed in prostate tumors, suggests that loss of PMEPA1 may play critical roles in prostate tumorigenesis. This study focuses on epigenetic mechanisms of reduced PMEPA1 expression in the cancer of the prostate (CaP). Benign (n = 77) and matched malignant (n = 77) prostate epithelial cells were laser capture micro-dissected from optimum cutting temperature embedded frozen prostate sections from 42 Caucasian American (CA) and 35 African American (AA) cases. Purified DNA specimens were analyzed for CpG methylation of the PMEPA1 gene. PMEPA1 mRNA expression levels were evaluated by qRT-PCR. Analysis of PMEPA1 methylation and mRNA expression in the same tumor cell populations indicated a significant inverse correlation between mRNA expression and methylation in CaP (P = 0.0115). We noted higher frequency of CpG methylation within the evaluated first intronic region of the PMEPA1 gene in prostate tumors of CA men as compared with AA. In CaP cell lines, PMEPA1 expression was induced and AR protein levels were diminished in response to treatment with the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine (decitabine). Cell culture-based studies demonstrated that decitabine restores PMEPA1 expression in AR-positive CaP cell lines. This report reveals the potential role of PMEPA1 gene methylation in the regulation of AR stability. Thus, downregulation of PMEPA1 may result in increased AR protein levels and function in CaP cells, contributing to prostate tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.